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Gene editing of the erythroid-specific BCL11A enhancer in hematopoietic stem and progenitor 
cells (HSPCs) from sickle cell disease (SCD) patients induces fetal hemoglobin (HbF) without 
detectable toxicity as assessed by mouse xenotransplant. Here, we evaluated autologous 
engraftment and HbF induction potential of erythroid-specific BCL11A enhancer edited HSPCs 
in four non-human primates. We utilized a single guide RNA (sgRNA) with identical human and 
rhesus target sequences to disrupt a GATA1 binding site at the BCL11A +58 erythroid 
enhancer. Cas9 protein and sgRNA ribonucleoprotein complex (RNP) was electroporated into 
rhesus HSPCs, followed by autologous infusion after myeloablation. We found that gene edits 
persisted in peripheral blood (PB) and bone marrow (BM) for up to 101 weeks similarly for 
BCL11A enhancer or control locus (AAVS1) targeted cells. Biallelic BCL11A enhancer editing 
resulted in robust γ-globin induction, with the highest levels observed during stress 
erythropoiesis. Indels were evenly distributed across PB and BM lineages. Off-target edits were 
not observed. Non-homologous end-joining repair alleles were enriched in engrafting HSCs. In 
summary, we find that edited HSCs can persist for at least 101 weeks post-transplant and 
biallelic edited HSCs provide substantial HbF levels in PB red blood cells, together supporting 









The β-hemoglobin (HBB) disorders, including sickle cell disease (SCD) and β-thalassemia, are 
the most common single-gene inherited disorders, resulting in severe morbidity and mortality 
worldwide. The only curative therapeutic modality for these conditions is allogeneic 
hematopoietic stem cell transplantation (HSCT), which is limited by a shortage of matched 
donors (1) and may be associated with graft-versus-host disease. Induction of fetal hemoglobin 
(HbF) in adults with SCD has proven clinically beneficial for patients with severe disease 
because γ-globin inhibits hemoglobin (Hb) polymerization under deoxygenated conditions by 
incorporating into tetramers and decreasing sickle hemoglobin (HbS) concentration in red blood 
cells (RBCs) (2). In addition, a high level of HbF in β-thalassemia patients is associated with 
amelioration of disease severity as γ-globin improves α/β-chain imbalance and HbF replaces 
deficient adult hemoglobin (HbA) (3). Genome-wide association studies recognized BCL11A as 
a significant repressor of γ-globin expression (4, 5), and multiple lines of evidence have 
validated its negative regulatory activity (6, 7). In addition to its HbF silencing role, BCL11A is 
required for normal B-cell development and hematopoietic stem cell (HSC) function. We and 
others previously identified the intronic erythroid-specific BCL11A enhancer, itself subject to 
HbF-associated common genetic variation, as a favorable therapeutic target (8-12). We recently 
demonstrated that CRISPR-Cas9 disruption of the enhancer by indels (insertions and deletions 
introduced to the genome by DNA repair after targeted cleavage) induces HbF, inhibiting 
sickling and restoring globin chain balance in erythroid cells derived from hematopoietic stem 
and progenitor cells (HSPCs) from SCD and β-thalassemia patients respectively, without 
detectable genotoxicity or adverse effects on HSC function (12). Xenotransplantation of HSCs 
may not fully evaluate the self-renewal and peripheral blood (PB) repopulation potential required 
for an effective cellular therapy. In particular, xenotransplant assays may emphasize the 
function of progenitors over HSCs and do not support normal PB reconstitution. Since HbF is a 
recent evolutionary adaptation originating in a shared ancestor of humans and old-world non-
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human primates, its endogenous regulation cannot be modeled easily in non-primate cells. 
Therefore, non-human primate autologous hematopoietic cell transplantation may be a powerful 
experimental system where various gene manipulations may be investigated for their feasibility, 
safety, and efficacy, facilitating successful clinical development (13-15). To more fully 
investigate the clinical potential of autologous HSC gene editing, here we evaluated engraftment 
and HbF induction potential of erythroid-specific BCL11A enhancer editing using a non-human 
primate transplantation model (Rhesus macaque) in which Hb switching is conserved (16). 
Advantages of the rhesus macaque autologous HSC transplant (HSCT) model include 
similarities between rhesus macaques and humans in genomic profile, hematopoiesis, and 
erythropoiesis, as well as the possibility of measuring indels and HbF in PB and bone marrow 








Editing the BCL11A erythroid enhancer in rhesus CD34+ HSPCs induces γ-globin 
We previously employed pooled sgRNA screening in human erythroid precursors to 
identify a core GATA1 binding site in the BCL11A +58 DNAse I hypersensitive site that is 
required for γ-globin repression (9). Subsequently, we observed that electroporation of a nuclear 
localization signal (NLS) sequence modified form of SpCas9 (3×NLS-SpCas9) and chemically 
modified synthetic guide RNA #1617 producing cleavage directly within the GATA1 binding 
motif produced highly efficient indels that disrupted erythroid BCL11A expression and prevented 
HbF silencing in healthy donor and β-hemoglobinopathy patient cells without detectable 
genotoxicity or impairment of HSC function under xenotransplantation conditions (12). The 
protospacer and protospacer adjacent motif (PAM) sequences are identical at the human and 
rhesus #1617 target sequences within the BCL11A +58 enhancer. Since we began these 
rhesus studies before identifying 3×NLS-SpCas9 as a highly efficient RNP complex for HSPC 
editing, in our preliminary studies we delivered 2×NLS-SpCas9:sgRNA RNP to rhesus CD34+ 
HSPCs by electroporation. We observed efficient editing at the BCL11A enhancer (using 
sgRNA #1617), with 81-85% indels, and at a control locus AAVS1, with 89-96% indels (Figures 
1A, 1B). Following erythroid differentiation of rhesus CD34+ HSPCs, substantial γ-globin RNA 
induction was detected with BCL11A enhancer editing, with 51-83% γ-globin in BCL11A 
enhancer edited cells compared to 27-49% and 11-33% in non-electroporated and AAVS1 
control locus edited cells, respectively (P < 0.01, Figure 1C). Consistent with the RNA profiles, 
elevated γ-globin protein levels (54-77%, P < 0.01) were observed in BCL11A edited cells 
compared to non-electroporated (19-25%) and AAVS1 edited cells (15-24%), respectively 
(Figure 1D, Supplemental Figure 1A), indicating that BCL11A enhancer editing de-represses 
HbF expression in rhesus erythroid cells. No significant difference in RBC enucleation efficiency 
(44-47%) following erythrocyte differentiation and viability in electroporated cells (56-68%) was 
observed between groups (Supplemental Figure 1B, 1C). Furthermore, the colony-forming unit 
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(CFU) capacity of the cells was comparable between the BCL11A edited and control groups 
(Supplemental Figure 1D).  
To test the editing frequency in HSC and progenitor fractions, we sorted CD34+CD38-
CD90+CD45RA- (HSC-enriched population) and CD34+CD38+ (committed progenitors, HPCs) 
from CD34+ HSPCs 2 hours after RNP electroporation. Indel sequence analysis of 5-day 
cultured fractions revealed modestly reduced editing frequency in the HSC-enriched population 
(56%) compared to HPCs (72%) (Supplemental Figure 2). In addition, the 15-bp deletion, a 
predicted microhomology-mediated end joining (MMEJ) product (20), was particularly reduced 
in the HSC-enriched population as compared to HPCs (from 8% to 2%) while the predominant 
non-homologous end-joining (NHEJ) repair product, a +1 insertion, was similar in the two 
populations (33% and 34%, Supplemental Figure 2).   
 
Edited HSPCs produce long-term engraftment in rhesus macaques        
To assess engraftment and HbF induction potential of BCL11A enhancer editing, we 
used two cohorts of macaques, with two animals per cohort. In cohort 1, we performed 
competitive engraftment of BCL11A enhancer and AAVS1 edited CD34+ HSPCs to test the 
feasibility of the approach and long-term reconstitution of edited cells. Mobilized rhesus CD34+ 
HSPCs were electroporated with RNP composed of 2×NLS SpCas9 protein and either BCL11A 
enhancer targeting (#1617) or AAVS1 targeting sgRNA, followed by ex vivo culture for 48 h. 
Cells were harvested and freshly infused into rhesus monkeys following preparative conditioning 
with 2×5 Gy total body irradiation (Figure 1A). Using a small aliquot of cells reserved for ex vivo 
studies, marked induction in γ-globin protein level was observed in BCL11A edited erythroid 
cells (33-45%) compared to control groups (12-27%) as determined by reverse-phase high-
pressure liquid chromatography (RP-HPLC) and Hb electrophoresis, without a significant 
change in cell numbers among the BCL11A enhancer and AAVS1 edited groups 
(Supplemental Figure 3A-F).   
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After CD34+ HSPC infusion (n = 2, ZL25 and ZL22, 1.23-1.42×106 CD34+ HSPCs/kg) 
(Table 1), animals engrafted with typical autologous reconstitution kinetics, i.e. 2-3 weeks as 
evidenced by blood cell counts and Hb levels in PB (Supplemental Figure 4). There was a 
moderate reduction in indel frequencies over the first 12 weeks after transplantation (3-15%) 
compared to indels in the input cell product (17-44%). However, after 12 weeks, stable indel 
frequencies were detected for both BCL11A enhancer (~3-6%) and AAVS1 (~7-11%) in PB-
derived granulocyte and lymphocyte fractions of the edited animals (Figure 1E, 1F, 
Supplemental Figure 5A, 5B). Stable AAVS1 and BCL11A enhancer editing frequencies were 
found in ZL22 and ZL25 for up to 101 weeks (Supplemental Figure 5C, 5D) suggesting the 
absence of selective difference between BCL11A enhancer edited, AAVS1 edited, and non-
edited HSCs. Overall, these results appear consistent with previous observations that after ex 
vivo HSPC gene editing, indel frequencies in short-term engrafting progenitors often exceed 
those found in long-term engrafting HSCs (12, 21, 22). 
By performing sequence analysis on individual BM mononuclear cell (MNC)-derived 
hematopoietic colonies, we found the BCL11A enhancer indels in ZL22 were distributed as ~2/3 
in biallelic and ~1/3 in monoallelic edited colonies, whereas in ZL25 the BCL11A enhancer 
indels were distributed as ~15% biallelic and ~85% monoallelic edited colonies (Figure 1G). 
Blood cell counts returned to the normal range after autologous reconstitution (Supplemental 
Figure 4). In addition, gene editing did not change the frequency or distribution of BM MNC-
derived colonies from ZL25 and ZL22 as compared to an unedited control animal 
(Supplemental Figure 5E-G). 
To analyze γ-globin induction in edited animals, we performed RP-HPLC from PB over 
time. There was a substantial induction of γ-globin during the first 12 weeks post-transplantation 
(4.3-14.6%) that gradually decreased and stabilized at pre-transplantation levels (~0.5%) by 
around 20 weeks post-transplantation (Figure 1H). Unfortunately, ZL22 was diagnosed with 
radiation pneumonitis at 11 weeks of transplantation and euthanized at 13 weeks after the 
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transplantation, at which point γ-globin level was 7.5%. Transient γ-globin induction has been 
reported for conditions resulting in stress erythropoiesis such as recovery from anemia due to 
transient erythroblastopenia of childhood (23), BM transplantation (24), and phlebotomy (25, 
26). Autologous hematopoietic transplantation of rhesus macaques produces transient 
expression of γ-globin up to a maximum of 0.99-2.53% at 4-9 weeks of transplantation that 
stabilizes at pre-transplantation levels after 20 weeks post-transplantation (27), suggesting that 
most of the γ-globin induction observed in ZL22 and ZL25 was due to BCL11A editing.  
 
Stable engraftment with biallelic edited HSCs after low-dose autologous HSPC infusion  
To further investigate γ-globin induction potential of BCL11A editing in rhesus monkeys, 
we transplanted two monkeys with HSPCs edited solely at the BCL11A enhancer (n = 2, ZM26 
and ZM17) as cohort 2. We used 3×NLS-SpCas9, which in previous human HSPC studies was 
associated with highly efficient indel generation in engrafting HSCs (12). Furthermore, we 
cryopreserved HSPCs prior to infusion to more fully mimic an anticipated clinical protocol. 
Consistent with cohort 1 animals, these animals engrafted with typical kinetics, and rescued cell 
counts and Hb levels at 2-3 weeks post-transplantation similar to control transplanted animals 
(Supplemental Figure 4). Despite having high indel rates (84.9%) in the infusion product of 
ZM26, and robust ex vivo γ-globin induction (65.9% vs 24.7% in non-edited control), there was a 
significant drop in the indel frequencies (~25-30%) at 4 weeks post-transplantation that 
stabilized to ~5-16% at 28 weeks post-transplantation (Figure 2A, Supplemental Figure 6A-
C). For prior efficient autologous reconstitution by gene marked HSCs after lentiviral gene 
transfer, we have infused cell products of at least ~3x106 CD34+ HSPCs/kg (28, 29). The 
relatively low infused HSPC number of 1.78×106 CD34+ HSPCs/kg could have contributed to 
inefficient autologous engraftment of the edited cells (Table 1). We observed that the BCL11A 
enhancer indels were mainly distributed in biallelic edited BM MNC-derived colonies (~80%) as 
compared to monoallelic edited colonies (~20%) (Figure 2B). γ-globin expression in ZM26 
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peaked at 8.1% at 6 weeks post-transplantation but decreased to levels indistinguishable from 
control animals (~0.5%) 20 weeks after transplantation (Figure 2C). The clonogenic capacity of 
BM MNCs of ZM26 at 38 weeks post-transplant was similar to other edited and non-edited 
animals (Supplemental Figure 5E-I).  
 
Erythropoiesis stress induces substantial γ-globin levels in edited animals 
As γ-globin induction peaked in the first 12 weeks following transplantation, we 
hypothesized that stress erythropoiesis might be reinforcing BCL11A editing-related γ-globin 
induction. To test this idea, we phlebotomized edited animals (ZL25 and ZM26) along with non-
transplanted (ZL12 and ZM19) and lentivirally transduced (GFP vector) CD34+ HSPC 
transplanted (RQ7278 and RQ7674) control animals twice a week (20% of total blood volume) 
for 6 weeks. Following phlebotomy, we observed anemia and elevated reticulocyte counts, with 
peak reticulocytosis 2-5 weeks after onset of phlebotomy (Figure 2D, 2E), consistent with 
accelerated erythropoiesis kinetics. ZM26, the animal with ~6% indel frequency with indels 
mainly distributed within biallelic edited colonies (Figure 2B) demonstrated substantial γ-globin 
induction (from 0.6% to 4.4% after 6 weeks of phlebotomy) (Figure 2F). In contrast ZL25, the 
animal with ~3% indel frequency, with indels mainly distributed within monoallelically edited 
colonies (Figure 1G) showed more modest γ-globin induction (from 0.4% to 1% after 6 weeks of 
phlebotomy). Control non-transplanted and marker vector transduced transplanted animals 
showed minimal γ-globin induction (from ~0.2-0.3% to ~0.5-0.7% after 6 weeks of phlebotomy), 
Editing frequencies in ZL25 and ZM26 for both AAVS1 and BCL11A enhancer did not change 
during the phlebotomy experiment (Supplemental Figure 6D-F), indicating that stress 
erythropoiesis did not preferentially drive hematopoiesis from edited compared to non-edited 
cells. After terminating phlebotomy, γ-globin expression returned to pre-phlebotomy levels for all 
animals, along with stable indel frequencies (Figure 2F). Together, the phlebotomy and 
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autologous reconstitution results suggest a positive interactive effect between biallelic BCL11A 
enhancer editing and stress erythropoiesis with regard to γ-globin induction. 
 
Efficient engraftment of BCL11A edited HSPCs 
The indel frequency in the input cell product for ZM17, the second animal in cohort 2, 
was 80.9%. A higher HSPC dose of 6.06×106 CD34+ HSPCs/kg was infused to ZM17 (3.4-fold 
greater than infused to ZM26). Stable indel frequencies were detected in both PB granulocyte 
(75.1%) and lymphocyte (79.0%) fractions at 25 weeks post-transplantation (Figure 3A, 
Supplemental Figure 7A). Unfortunately, the animal ZM17 developed severe radiation 
pneumonitis and was euthanized at 28 weeks. 83.6% of edited BM MNC colonies had biallelic 
indels, 9.8% had monoallelic indels, and 6.6% were unedited (Figure 3B). γ-globin expression 
in PB reached up to 28.6% at 7 weeks post-transplantation (Figure 3C). Like the other animals, 
γ-globin in ZM17 decreased after autologous transplant, nadiring at 9.9% at 25 weeks and then 
12.7% at 28 weeks post-transplantation. Comparing all four edited animals, there was a strong 
correlation between BCL11A enhancer indel frequencies and peak γ-globin levels in peripheral 
blood during the first 13 weeks following transplantation (R2 = 0.73, P < 0.001, Figure 3D).   
BCL11A plays critical roles in B-lymphocyte maturation and HSC self-renewal (30-32). 
The rationale of editing the BCL11A erythroid enhancer is to minimize impact on non-erythroid 
hematopoietic functions. To test any selective impact of BCL11A enhancer editing on various 
hematopoietic lineages, different cell fractions from both PB and BM MNCs of ZM17 at 28 
weeks post-transplantation were sorted and subjected to deep sequencing. The BCL11A 
enhancer indel frequencies ranged from 78-81% across all PB and BM lineages (excluding 
CD3+ T-cells with 63% indels), including CD20+ B-lymphoid, CD14+ myeloid cells, CD34+ 
HSPCs, and CD71+ CD45- erythroblasts, suggesting no selective toxicity to any cell lineage 
tested (Figure 3E, 3F).  
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We further analyzed the subset of specific gene edit alleles for which the frequency was 
at least 1% in one lineage, comprising 14 indels plus the unedited allele. Overall, the distribution 
of gene edits showed a very similar pattern among all hematopoietic lineages, suggesting the 
absence of strong lineage-specific selection pressure (Supplemental Figure 8A). In order to 
measure the similarity among cell subpopulations, we performed an unsupervised hierarchical 
clustering analysis (using Ward distance) on normalized (z-scored) edit frequencies (Figure 
3G). The lineages were grouped in 3 main clusters: 1) CD3+ T-cells in BM and PB; 2) all other 
PB lineages plus BM CD20+ B-cells; and 3) all other BM lineages. Multiple factors might 
contribute to this clustering configuration, such as the hierarchical nature of hematopoietic 
differentiation and heterogeneity in lifespan of lineage-biased HSPCs. We also tested the 
correlation (Pearson’s coefficient) among all possible pairs of lineages using the edit frequency 
data (Supplemental Figure 8B, Supplemental Tables 1-2). BM and PB CD3+ T-cells showed 
a significant positive correlation with each other and negative association with PB CD14+ 
monocytes and PB granulocytes. Positive association was also measured among: BM CD14+ 
monocytes and BM granulocytes; BM monocytes and CD71+ CD45- erythroblasts; and all PB 
lineages (besides CD3+ T cells). 
Peripheral blood counts, including Hb level and reticulocyte counts of ZM17 at 6 months 
post-transplantation were not different from those of untransplanted controls (ZL12 and ZM19) 
and GFP expressing lentivirus transduced CD34+ HSPC transplanted animals (RQ7278 and 
RQ7674) (Figure 3H, Supplemental Figure 4). Furthermore, similar clonogenicity of BM MNCs 
collected at 28 weeks post-transplantation was observed as compared to other edited animals 
and the control non-transplanted animal (Supplemental Figure 5E-I). Together, these data do 
not indicate apparent hematologic or erythroid effects of BCL11A enhancer editing aside from γ-
globin induction.  
 The most common alleles in rhesus HSPCs after BCL11A enhancer editing were a 1-
base pair (bp) T insertion, produced by non-homologous end joining (NHEJ) repair, followed by 
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a -15 bp deletion, produced by MMEJ repair (Supplemental Figure 9-10). These predominant 
edits were the same as observed in human HSPCs after BCL11A enhancer editing with the 
identical sgRNA (12). Previously we observed that engrafting human hematopoietic cells in 
mouse xenografts preferentially carried NHEJ repair alleles as compared to MMEJ repair 
alleles. To evaluate the engraftment potential of HSPCs repaired by NHEJ as compared to 
MMEJ, we analyzed individual gene edit alleles in input HSPCs and engrafting granulocytes and 
lymphocytes (Supplemental Figure 9A-F). We observed that overall edits were variably 
reduced in the 4 animals comparing the input cell products to engrafting cells (Supplemental 
Figure 9, 11). In each animal, we observed that the fraction of MMEJ alleles at the BCL11A 
enhancer was selectively reduced (1.6 - 4.5-fold) in engrafted cells as compared to the input cell 
product (Figure 4A, Supplemental Figure 11). Similar selective reduction of MMEJ repair 
alleles in engrafting cells (3.4 - 3.9-fold) was also observed after AAVS1 editing (Figure 4B, 
Supplemental Figure 9A, 9C, 11).  
We calculated the population diversity of gene edit alleles (excluding the unedited allele) 
as measured by the Shannon H index (33) in each input cell product and engrafted granulocyte 
and lymphocyte sample. We found that for each animal and sgRNA, there was a consistent 
reduction in the diversity in the engrafted cells with respect to the input cell product (Figure 4C, 
4D, Supplemental Table 3). For ZM17, after the initial drop, the diversity of the edited cell 
population stabilized around H = 2.6, similar for both granulocytes and lymphocytes. This 
suggests a polyclonal distribution in which: 1) a considerable number of cells bearing different 
edits engrafted (~250 alleles); 2) the number of alleles with a significant abundance was high; 3) 
the composition of this population was constant over time; and 4) any in vivo selection acts 
similarly in the two lineages. For all other animals, the clonality index decreased over time, 
approaching H < 1, suggesting that the edited cell populations lost more substantial complexity 
and heterogeneity, tending to an oligoclonal distribution, relative to ZM17. The number of 
detected edits in the engrafted population reduced over time to ~10-40 alleles, with few alleles 
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having high relative abundance. In lymphocytes, Shannon’s H index decreased more slowly as 
compared to granulocytes, perhaps due to differences in the lifespan of lineage-biased 
progenitors in the input product or to a slower turnover of lymphocytes. For animals ZL22 and 
ZL25, the AAVS1 and BCL11A enhancer edits showed similar clonality dynamics. The H-index 
at week 12 was positively correlated to infused cell number, consistent with observations from 
human hematopoietic gene therapy that infused cell number is a key determinant of polyclonal 
engraftment of gene marked cells (R2 = 0.86, Figure 4D) (34). 
We performed CIRCLE-seq (35) to empirically define rhesus genomic sites susceptible 
to off-target in vitro RNP cleavage. Then we performed amplicon deep sequencing of the top 26 
candidate off-target sites (based on CIRCLE-seq read counts) in each of the 4 input BCL11A 
enhancer edited input cell products as well as in engrafted hematopoietic cells. Despite 
detecting robust on-target BCL11A enhancer editing in each sample, we did not observe off-
target gene editing at any of these 26 sites in any of the samples, at a limit of detection of 0.1% 





Developing innovative autologous hematopoietic cell transplantation protocols in rhesus 
macaques is especially complex in that the procedures and reagents for HSC mobilization, 
collection, gene modification, culture, and re-engraftment are largely adapted from protocols 
initially optimized for human cells. One challenge we encountered was to achieve consistently 
safe and effective myeloablation (36, 37), with two animals succumbing to radiation 
pneumonitis. Furthermore, we obtained variable recovery from mobilized peripheral blood cell 
apheresis. Three of the four infusion cell products included fewer than the typical target of 3x106 
CD34+ HSPCs/kg (Table 1), which might disadvantage the engraftment of the cell product as 
compared to residual HSCs. Despite these challenges, by investigating just 4 animals, we 
observed improved gene-editing efficiency from ~30-40% to ~80-85% indels in the input cell 
product at scale to support autologous hematopoietic transplantation following myeloablative 
conditioning therapy. We demonstrated a proof-of-principle for therapeutic gene editing with 
~70-80% gene modifications in engrafting hematopoietic cells after 28 weeks, mainly distributed 
as biallelic edits. This result is the most efficient autologous hematopoietic gene editing 
achieved in non-human primates to our knowledge. Prior reports demonstrated substantially 
fewer gene edits in engrafting hematopoietic cells (14, 21). In a previous NHP setting, editing of 
the CCR5 gene dropped from 40% in the infusion product to 3-5% at 6 months (22). A recent 
study aiming to induce HbF by creating hereditary persistence of fetal hemoglobin (HPFH) 
mutation in rhesus macaques showed a decrease in indels from ~70% in the input cell product 
to ~15% in engrafting cells (21). These results suggest that at intermediate editing frequencies, 
indels in unfractionated autologous HSPCs also may overestimate those in engrafting HSCs 
(12). A non-mutually exclusive possibility could be incomplete hematopoietic ablation with partial 
reconstitution by residual non-ablated HSCs. These results encourage the development of gene 
editing protocols to maximize both the total number and fraction of biallelically modified HSCs. 
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We observed selective reduction of MMEJ repair alleles in engrafting compared to input 
cells. This result suggests that HSCs, a rare subset within HSPC cell products, preferentially 
repair by NHEJ. NHEJ repair with short indels appears sufficient to disrupt BCL11A enhancer 
function and support HbF induction in erythroid progeny of edited HSCs. We found that BCL11A 
enhancer editing yielded robust induction of γ-globin during steady-state erythropoiesis, with 
~18-fold increase from unedited steady-state level in the same animal (Figure 3C, 
Supplemental Figure 7B). In addition, we observed a substantial positive interaction between 
BCL11A enhancer editing and stress erythropoiesis associated with hematopoietic repopulation, 
with an additional 2.8 - 6.8-fold increase as compared to the steady-state levels in the edited 
animals. During phlebotomy induced erythroid stress, we observed HbF induction only in ZM26, 
the animal with BCL11A enhancer edits mainly distributed as biallelic indels, also consistent 
with a positive interaction between erythroid stress and BCL11A modulation. Future studies 
appear warranted to further explore this interaction. In the setting of HbF induction for β-
hemoglobinopathy patients as compared to healthy individuals, we anticipate there may be 
additional contributions from both disease-associated stress erythropoiesis as well as survival 
advantage of HbF expressing erythrocytes and precursors. Together, we predict these effects, 
plus more pancellular than heterocellular distributions of gene edits, could further magnify the 
impact of HbF induction following BCL11A enhancer editing in β-hemoglobinopathy patients.  
For all animals and guide RNAs (including targeting both AAVS1 and BCL11A 
enhancer), we observed a reduction of the diversity of gene edits in the engrafted cells with 
respect to the input cell product. The starting cell product was relatively complex, with edits 
more evenly distributed. The engrafted cells had fewer edits, suggesting a bottleneck in the 
initial engrafting cell population, that then stabilized over extended examination. Cell products 
with greater HSPC numbers were associated with more polyclonal engraftment. These 
dynamics appear reminiscent of gene therapy with HSCs marked by lentiviral insertions. 
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Under efficient editing conditions, we observed a similar distribution of BCL11A 
enhancer indels across all PB and BM lineages (with exception of modestly lower frequency of 
gene editing in long-lived CD3+ T-lymphocytes) suggesting no skewed hematopoietic 
contributions of BCL11A enhancer gene-edited cells. Moreover, we observed normal blood 
counts including no anemia or hemolysis following efficient BCL11A enhancer editing, 
consistent with intact hematopoiesis and erythropoiesis. Off-target genotoxicity is one possible 
concern of therapeutic gene editing. We did not observe any off-target gene edits attributable to 
BCL11A enhancer editing, although large deletions and rearrangements were not specifically 
evaluated (38). These findings are similar to the absence of apparent toxicity of BCL11A 
enhancer editing with 3×NLS-SpCas9 and sgRNA-#1617 in human HSPCs (12). 
In summary, we evaluated the clinical potential of autologous BCL11A erythroid 
enhancer editing in rhesus macaques. BCL11A enhancer edited HSCs can persist for at least 
101 weeks post-transplant and provide potentially therapeutic levels of HbF in PB RBCs without 
anemia or other apparent hematologic toxicity. These results emphasize that gene editing 
efficiency and repair mode, input CD34+ HSPC number and conditioning therapy are each 
critical variables that influence gene edits in engrafted hematopoietic cells following autologous 
HSCT. Overall, these findings support BCL11A erythroid enhancer genome editing as a 





Detailed methods are provided in the Supplemental Methods. All raw sequence data have been 




Rhesus macaques (Macaca mulatta) were housed and handled in accordance with the 
guidelines set by the Committee on Care and Use of Laboratory Animals of the Institute of 
Laboratory Animal Resources, National Research Council, and all animal protocols were 
approved by the Animal Care and Use Committee of the National Heart, Lung, and Blood 
Institute-NHLBI (approved protocol no: H-0136R4). 
 
Statistics 
Standard errors of the mean are given as error bars in all f igures. The data were statistically 
analyzed with one-way analysis of variance (ANOVA) followed by the Tukey post hoc test using 
GraphPad Prism 7 software (GraphPad Software, Inc, USA). Data were considered significantly 
different at p < 0.05. Clonality index and lineage data analysis were performed by means of R 
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Figure 1. Durable autologous engraftment following BCL11A enhancer gene editing. (A) 
Schematic representation of electroporation of rhesus CD34+ HSPCs with ribonucleoprotein 
(RNP) complex composed of 2×NLS SpCas9 or 3×NLS SpCas9 protein, and either BCL11A 
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enhancer targeting (#1617) or AAVS1 targeting sgRNA. The cells are either used for ex vivo 
analysis or autologous transplantation. (B) Editing efficiency measured by Sanger sequencing 
with TIDE analysis, and (C) β-like globin RNA expression by RT-qPCR normalized to α-globin 
expression in non-edited (Mock), AAVS1 and BCL11A edited rhesus CD34+ HSPCs in small 
scale (ZL24 and ZL25, 5×104 cells, 200 pmol for both SpCas9 and sgRNAs) and large scale 
(ZL57, 5×106 cells, 1000 pmol for both SpCas9 and sgRNAs) electroporation conditions. (n=3, 
one-way analysis of variance (ANOVA) followed by the Tukey post hoc test, **, P < 0.01) (D) β-
like globin protein expression by reverse phase-high performance liquid chromatography (RP-
HPLC), (n=3, one-way analysis of variance (ANOVA) followed by the Tukey post hoc test, ** P < 
0.01). ZL25 and ZL22 were transplanted with AAVS1 and BCL11A enhancer edited cells (1:1). 
The gray rectangle represents the phlebotomy course. Editing frequencies in granulocytes for 
(E) AAVS1 and (F) BCL11A enhancer in transplanted rhesus macaques. Slopes were 
calculated separately for the first 13 weeks of transplantation (early progenitor phase) and later 
time points (HSC phase) as indicated by the dashed line. (G) Distribution of monoallelic and 
biallelic edited colonies collected from methylcellulose plates for bone marrow mononuclear 
cells of ZL25 at 100 weeks and ZL22 at 13 weeks post-transplantation. (H) γ-globin protein 













Figure 2.  Stress erythropoiesis cooperates with BCL11A enhancer editing to amplify γ-
globin induction. (A) Editing frequencies in granulocytes of ZM26 transplanted with BCL11A 
edited CD34+ HPSCs. Slopes were calculated separately for the first 13 weeks of 
transplantation (early progenitor phase) and later time points (HSC phase) as indicated by the 
dashed line. (B) Distribution of monoallelic and biallelic edited colonies collected from 
methylcellulose plates for bone marrow mononuclear cells of ZM26 at 38 weeks post-
transplantation. (C) γ-globin protein expression in ZM26. The gray rectangle represents the 
phlebotomy course. (D) Hematocrit (HCT), (E) reticulocyte, and (F) γ-globin protein percentages 
in phlebotomized non-transplanted (ZL12 and ZM19), lentivirus (GFP vector) transduced CD34+ 
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Figure 3.  Robust BCL11A enhancer editing and γ-globin induction. (A) Editing frequencies 
in granulocyte fraction in ZM17. Slopes were calculated separately for the first 13 weeks of 
transplantation (early progenitor phase) and later time points (HSC phase) as indicated by the 
dashed line. (B) Distribution of monoallelic and biallelic edited colonies collected from 
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methylcellulose plates for bone marrow (BM) mononuclear cells of ZM17 at 28 weeks post-
transplantation. (C) γ-globin protein expression by reverse phase-high performance liquid 
chromatography (RP-HPLC) in peripheral blood (PB) of ZM17. (D) Correlation of editing 
frequencies in all transplanted animals (4-13 weeks post-transplantation) with γ-globin protein 
expression by RP-HPLC. (E) Editing frequencies in BM-derived CD3+ T-cells, CD14+ 
monocytes, CD20+ B-cells, CD34+ HSPCs, CD71+ CD45- erythroblasts, and granulocytes and 
monocytes sorted using FSC A and SSC A. (F) Editing frequencies in PB-derived granulocytes, 
monocytes, CD3+, CD14+, and CD20+ cells. (G) Heatmap representation for normalized alleles 
abundance values among BM and PB lineages of ZM17 at 28 weeks post-transplantation. The 
allele-specific average abundance value (log) is represented by a gray-scale color on the left 
side of the heatmap. Both columns (lineages) and rows (alleles) are ordered according to their 
similarity measured by Ward distance. (H) Hemoglobin (Hb) and reticulocyte count percentages 
in non-transplanted (ZL12 and ZM19), lentivirus (GFP vector) transduced CD34+ HSPC 
















Figure 4. Gene editing dynamics after BCL11A enhancer editing. Relative loss of engrafted 
edits repaired by MMEJ in transplanted animals for (A) BCL11A enhancer and (B) AAVS1 
alleles. Deletions >8 bp were categorized as MMEJ, while all other indels were categorized as 
NHEJ. (C) Shannon diversity index (H) for edit distribution in input cell products and engrafted 
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samples. Granulocytes and lymphoid lineage data are plotted symmetrically, with the former on 
left (for animal ZL22 and ZL25, both BCL11A enhancer and AAVS1 are reported; for ZM17 and 
ZM26, only BCL11A enhancer data), and (D) Correlation of Shannon diversity index (H) with 
infusion cell dose in all transplanted animals (12-13 weeks post-transplantation). Granulocytes 
(Circles), Lymphocytes (Squares), BCL11A Enhancer (Filled shapes), AAVS1 (Open shapes). 
(E) Off-target analysis of granulocyte in edited animals transplanted with BCL11A enhancer 
edited CD34+ HSPCs. Using CIRCLE-Seq, 26 potential genomic off-target sites for BCL11A 
enhancer guide #1617 were identified. Editing frequencies at the 26 sites were evaluated 
through amplicon deep sequencing and analysis. The samples include the infusion product 
(input) and granulocyte fraction of a later peripheral blood collection for each rhesus macaque. 





Supplemental Figure 1. BCL11A enhancer editing induces γ-globin in rhesus CD34+ 
HSPCs without affecting colony-forming unit (CFU) formation ability and enucleation. (A) 
Hemoglobin (Hb) electrophoresis and (B) enucleation percentages for ex vivo differentiated red 
blood cells (RBCs) in non-edited (Mock) and edited (AAVS1 or BCL11A enhancer) rhesus 
CD34+ HSPCs. (n=3, one-way analysis of variance (ANOVA) followed by the Tukey post hoc 
test) (C) Cell viability of electroporated rhesus CD34+ HSPCs edited for AAVS1 or BCL11A 
enhancer in small scale (ZL24 and ZL25, 5×104 cells, 200pmol for both 2×NLS SpCas9 and 
sgRNAs) and large scale (ZL57, 1.5×106 cells, 1000pmol for both 2×NLS SpCas9 and sgRNAs) 
electroporation conditions. (D) CFU formation ability of CD34+ HSPCs incubated 48 h in ex vivo 
culture conditions after electroporation with RNP. (n=5, one-way ANOVA followed by the Tukey 







Supplemental Figure 2. Slightly lower indels in the HSC-enriched population with higher 
indel frequencies repaired by NHEJ compared to committed progenitors. Indel spectrum of 
rhesus CD34+ HSPCs sorted 2 hours after RNP electroporation for HSC-enriched population 
(CD34+CD38-CD90+CD45RA-) and committed progenitors (CD34+CD38+). Sanger sequences 







Supplemental Figure 3. Ex vivo γ-globin induction in BCL11A enhancer edited rhesus 
CD34+ HSPCs before transplantation. (A) Cell number (n=3) and β-like globin protein 
expression by (B) reverse phase-high performance liquid chromatography (RP-HPLC) and (C) 
hemoglobin (Hb) electrophoresis in ex vivo differentiated ZL25 CD34+ HSPCs before 
transplantation. (one-way analysis of variance (ANOVA) followed by the Tukey post hoc test, * P 
< 0.05, ** P < 0.01).  (D) Cell number (n=3) and β-like globin protein expression by (E) RP-












Supplemental Figure 4. Typical autologous reconstitution kinetics following BCL11A 
enhancer gene editing.  BCL11A enhancer edited CD34+ HSPC transplanted animals (ZL25, 
ZL22, ZM26, and ZM17) rescued their cell counts and hemoglobin (Hb) levels with typical 
kinetics similar to control animals transplanted with lentivirus (GFP vector) transduced CD34+ 
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HSPCs (RQ7277 and RQ7375). The black arrow indicates platelet transfusion and the blue 




























Supplemental Figure 5. Durable autologous engraftment and colony-forming unit (CFU) 
potential following BCL11A enhancer gene editing. ZL25 and ZL22 were transplanted with 
AAVS1 and BCL11A enhancer edited cells (1:1). The gray rectangle represents the phlebotomy 
course. Editing frequencies in lymphocyte (LYM) fractions for (A) AAVS1 and (B) BCL11A 
enhancer in transplanted rhesus macaques. AAVS1/1617 editing ratio in (C) granulocyte (GR) 
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and (D) LYM fractions of the transplanted animals. CFU potential of BM MNCs of (E) ZL25 at 
100 weeks post-transplantation (n=6), (F) ZL22 at 13 weeks post-transplantation (n=6), (G) a 
non-transplanted control animal, ZI07 (n=4), (H) ZM26 at 38 weeks post-transplantation (n=6), 


























Supplemental Figure 6. Stable gene editing dynamics after transplantation and during 
phlebotomy.  (A) Reverse-phase high-performance liquid chromatography (RP-HPLC) and (B) 
hemoglobin (Hb) electrophoresis analysis for β-like globin protein expression evaluation in ex 
vivo differentiated red blood cells (RBCs) of non-edited (Mock) and BCL11A enhancer edited 
rhesus CD34+ HSPCs of ZM26 before transplantation. (C) Indel frequencies in the lymphocyte 
(LYM) fraction of ZM26 over time. Indel percentages during the phlebotomy course for (D) 
AAVS1 and (E) BCL11A enhancer in ZL25, and (F) BCL11A enhancer in ZM26 for granulocytes 












Supplemental Figure 7. Robust BCL11A enhancer editing and γ-globin induction. (A) 
Indel frequencies in lymphocyte fraction of ZM17 over time. (B) γ-globin protein expression in 
animals transplanted with lentivirus transduced (GFP/YFP vector) (DEFM, DFRM, ZJ32, and 





















Supplemental Figure 8. Cell lineage gene edit patterns. (A) Heatmap representation of the 
abundance (log) for the 14 indels with a frequency greater than 1% in at least one lineage plus 
the unedited allele in BM and PB lineages of ZM17 at 28 weeks post-transplantation. The allele-
specific average abundance value (log) is represented by a gray-scale color on the left side of 
the heatmap. Both columns (lineages) and rows (alleles) are ordered according to their similarity 
measured by Ward distance. (B) The correlation (Pearson’s coefficient) among all possible pairs 
of lineages of ZM17 at 28 weeks post-transplantation based on gene edit distribution. Both 
circle diameter and color represent Pearson’s correlation estimates. Only significant (t-test, 






























Supplemental Figure 9. Summary of the indel composition in engrafted granulocyte and 
lymphocyte fractions of peripheral blood over time. Amplicon deep sequencing and analysis 
was performed to identify (A) AAVS1 edits in ZL25, (B) BCL11A enhancer edits in ZL25, (C) 
AAVS1 edits in ZL22, (D) BCL11A enhancer edits in ZL22, (E) BCL11A enhancer edits in ZM26, 
and (F) BCL11A enhancer edits in ZM17. The 30 alleles with the highest frequency in each 
sample are shown. In: Infusion product, MMEJ: Microhomology-mediated end joining, NHEJ: 
Non-homologous end joining. The measured edits in the infusion products for ZL25 and ZL22 
were divided by two in these plots to reflect the 1:1 mixing of AAVS1 and BCL11A enhancer 








Supplemental Figure 10. Similar indel compositions of BCL11A enhancer edits in bone 
marrow (BM) and peripheral blood (PB) lineages. Amplicon deep sequencing and analysis 
was performed to identify BCL11A enhancer edits in BM (CD14+, CD20+, CD3+, CD34+, 
CD45-CD71+, granulocyte [Gr] and monocyte [Mono]) and PB (CD14+, CD20+, CD3+, 
granulocyte [Gr] and monocyte [Mono]) fractions of ZM17 over time. For each fraction, amplicon 
deep sequencing and indel analysis were performed, and the 30 alleles with the highest 
frequency are shown. In: Infusion product, MMEJ: Microhomology-mediated end joining, NHEJ: 









Supplemental Figure 11. Microhomology-mediated end joining (MMEJ)  and non-
homologous end joining (NHEJ) indel percentages in edited animals over time. Deletions 




Table 1. Summary of gene edited autologous transplantation experiments. 
Animal ZL25 ZL22 ZM26 ZM17 
Age at transplantation/Sex 4.5/M 5.5/M 4.5/M 4.0/F 
Cas9 2×NLS SpCas9 2×NLS SpCas9 3×NLS SpCas9 3×NLS SpCas9 
Guide RNA AAVS1, BCL11A enhancer (#1617) 






RNP concentration (µM) 10 10 10 10 
Apheresis cell number 
(cells/kg)  3.50×10
6 0.26×10
6 (day 1); 2.53×106 (day 
2) 
2.50×106 (day 1); 
1.47×106 (day 2) 
4.12×106 (day 1); 
6.93×106 (day 2) 
Electroporation cell 
concentration (cells/ml) 5.00×10
6 5.00×106 1.50×106 1.50×106 
Pre-EP culture time (h) 0 24 24 24 
Post-EP culture time (h) 48 48 48 48 
Culture plate coating Retronectin None None None 




0.58×106 (AAVS1); 0.65×106 
(BCL11A enhancer) 1.78×10
6 6.06×106 
Infusion type  Fresh cells Fresh cells Cryopreserved cells 
Cryopreserved 
cells 
Infusion product indel 
frequency 
73.4% (AAVS1);  
40.4% (BCL11A enhancer) 
87.8% (AAVS1);  
33.2% (BCL11A enhancer) 84.9% 80.9% 
 
Note: Indels in the infusion products are measured prior to mixing AAVS1 and BCL11A enhancer edited cells  
